The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
Artificial lyo-vials are provided that include a portion of a vial. The portion of the vial includes a vial wall with a top end opening and a bottom end opening. The bottom end opening includes an inside diameter that is greater than an inside diameter of the top end opening. At least a portion of the vial wall is translucent. The artificial lyo-vials include an artificial lyo-cake. The artificial lyo-cake is secured within the portion of the vial. The artificial lyo-cake includes a base, an annular surface, a top surface, and a longitudinal dimension extending from the base to at least a portion of the top surface. An outside diameter of the artificial lyo-cake is greater than the inside diameter of the top end opening.
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
useful for the synthesis of compounds that target KRAS G12C mutations, such as
The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure
useful for the synthesis of compounds that target KRAS G12C mutations, such as
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
AMGEN INC. (USA)
Inventor
Smyth, Hugh
Nair, Varsha
Li, Weikun
Ding, Li
Abstract
Disclosed herein are compositions comprising a plurality of particles, which include dry powder compositions, and unit dose packages, blister packages, and dry powder inhaler devices comprising the dry powder compositions, methods of treating certain disorders, such as respiratory diseases, using the dry powder compositions, and methods of making the dry powder compositions.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Adapters for resealing an ampoule after it has been broken open and related methods are disclosed. The adapter may include a body portion configured to receive at least a portion of the ampoule, a proximal open end, and a distal open end. The adapter may further include one or more inner seal members disposed at least partially within the body portion and configured to sealingly engage an outer surface of the ampoule. Furthermore, at least when the adapter is in an assembled or functional state, the adapter may include a cap or end seal member which covers the distal open end of the body portion. The one or more inner seal members and the end seal member may be configured to at least partially define a sealed interior space in which an open end of the ampoule can be safely stored.
Provided herein are processes for preparing Compound A or a salt thereof, comprising admixing Compound B or a salt thereof and crotonaldehyde in the presence of an acid catalyst and a solvent to form Compound A
Provided herein are processes for preparing Compound A or a salt thereof, comprising admixing Compound B or a salt thereof and crotonaldehyde in the presence of an acid catalyst and a solvent to form Compound A
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 213/73 - Unsubstituted amino or imino radicals
The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, such as nonalcoholic fatty liver disease (NAFLD), are also described.
A drug delivery device includes a housing having proximal and distal ends and a longitudinal axis extending therebetween, an injection assembly at least partially disposed within the housing at or near the proximal end thereof and including a needle or a cannula, a shield slidably coupled with the housing, a drive assembly at least partially disposed within the housing, and a depth adjuster operably coupled with the shield and/or the housing. The shield is positionable in an extended position in which at least a proximal end extends a distance beyond the proximal end of the housing and a retracted position. The drive assembly is operably coupled with the injection assembly and the shield and is engageable to deliver a medicament via the injection assembly. When coupled with the shield and/or the housing, the depth adjuster is adapted to prevent or resist the shield from being positionable in the retracted position.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
9.
METHODS OF TREATING HEART FAILURE BY ADMINISTERING OMECAMTIV MECARBIL
Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt of a hydrate thereof.
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S. G13D, Q61H. Q61L or G12C. The compunds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A system for validating a device under test using a testing system having a testing component. The system may be configured to obtain a model of a testing component having a tolerance that impacts test results for a test performed by the testing system, determine an absolute component tolerance metric associated with a dimension of a testing component of the testing system, determine a test result delta based upon the absolute component tolerance metric associated with the dimension of the testing component, obtain a historical test results dataset indicative of historical tests performed using the testing system, generate a plurality of adjusted test results datasets via a Monte Carlo simulation, determine a plurality of sets of statistical characteristics respectively corresponding to the plurality of adjusted test results datasets, and determine acceptance or failure of the device under test based upon the plurality of sets of statistical characteristics.
G06F 119/02 - Reliability analysis or reliability optimisationFailure analysis, e.g. worst case scenario performance, failure mode and effects analysis [FMEA]
12.
STABILIZING HOMODIMER MUTATIONS FOR TWO CELL HETERODIMER PRODUCTION
The present invention relates to methods of producing homodimers comprising mutations in the CH3 domains. Said mutations increase the stability of the homodimer, resulting in increased homodimer yield. Said homodimers are separately expressed and purified, and reassembled into heterodimers.
A packaging for drug administration comprises a carton having a storage configuration and an assembled configuration. The carton comprises a bottom box having a first bottom wall, a first sidewall, a second sidewall, a first back wall, and a first front wall when the carton is in the assembled configuration, and a lid coupled to the bottom box and movable between an open position and a closed position. The packaging also comprises a tray configured to be disposed within the bottom box of the carton. The tray also has a storage configuration and an assembled configuration. In the assembled configuration, the tray comprises a plurality of cavities dimensioned to house one or more drug delivery components.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Injectors for medical purposes pre-filled with pharmaceutical preparations for treating oncology, hematology, cardiovascular, metabolic and inflammatory diseases and conditions Injectors for medical purposes, namely, medical fluid injectors
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Injectors for medical purposes pre-filled with pharmaceutical preparations for treating oncology, hematology, cardiovascular, metabolic and inflammatory diseases and conditions Injectors for medical purposes, namely, medical fluid injectors
16.
DIRECT CHARACTERIZATION OF SUBVISIBLE PARTICLES IN DRUG PRODUCTS WITH NON-INVASIVE MIE-SCATTERING-BASED LIGHT SHEET TECHNOLOGY
Described herein are systems for determining an absence, or presence and size of particles in a liquid pharmaceutical product. The systems may comprise a Mie-scattering-based light sheet (MSLS) liquid particle analyzer. Described herein are method for determining an absence, or presence and size of particles in a liquid pharmaceutical product.
The present invention is directed to a CH3-containing molecule comprising (a) a first polypeptide comprising a CH3 domain and a negatively charged domain comprising consecutive negatively charged amino acid residues; and (b) a second polypeptide comprising a CH3 domain and a positively charged domain comprising consecutive positively charged amino acid residues. Also provided are methods for conjugating synthetic molecules to a multi-specific antigen binding molecule.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are methods of producing an antibody composition comprising a desired or predetermined or pre-selected level of total afucosylated (TAF) glycoforms. In exemplary embodiments, the method comprises maintaining glycosylation-competent cells in a cell culture medium comprising fucose and/or glucose at a specific concentration as described herein, depending on the level of TAF glycoforms desired. Related compositions comprising glycosylated proteins and TAF glycoforms thereof are also provided herein. Also provided are cell culture media.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A computer-implemented method can comprise, at a display device, displaying, via the display device, a first user interface corresponding to one or more molecules; receiving, via the display device, one or more first user inputs associated with the one or more molecules, wherein the one or more first user inputs comprise selecting a subset of the one or more molecules; and in response to selecting the subset of the one or more molecules, displaying, via the display device, a second user interface corresponding to a form map associated with the subset of the one or more molecules.
G06F 3/04817 - Interaction techniques based on graphical user interfaces [GUI] based on specific properties of the displayed interaction object or a metaphor-based environment, e.g. interaction with desktop elements like windows or icons, or assisted by a cursor's changing behaviour or appearance using icons
G16B 15/30 - Drug targeting using structural dataDocking or binding prediction
G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
20.
RADIOLABELED COMPOUNDS FOR THE DETECTION OF STEAP1
The present invention relates to anti-STEAP1 constructs for the use of detecting STEAP1 in a subject. The invention further relates to anti-STEAP1 (Fab')2 fragments that are radiolabeled. Said constructs are useful for imaging STEAP1 expression, for example, in a positron emission tomography scan.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
21.
OPTIMIZATION OF MOTION PROFILE USING COMPUTATIONAL FLUID DYNAMICS
Methods for optimizing a motion profile for agitating a sample in a container and systems implementing the methods are described herein. The methods may include (a) obtaining a motion profile associated with an agitation event of the container; (b) analyzing the motion profile using a computational fluid dynamics (CFD) model to generate one or more performance metrics of the agitation event, wherein generating the performance metrics includes generating a coverage of an inner surface of the container that experienced a threshold amount of wall shear stress; (c) comparing the one or more performance metrics to one or more respective acceptance criteria to determine an acceptability of the motion profile; and (d) based on the comparison, performing one of (i) accepting the motion profile, or (ii) adjusting the motion profile and repeating steps (b)-(d) using the adjusted motion profile.
G06F 30/28 - Design optimisation, verification or simulation using fluid dynamics, e.g. using Navier-Stokes equations or computational fluid dynamics [CFD]
G01N 21/90 - Investigating the presence of flaws, defects or contamination in a container or its contents
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Injectors for medical purposes pre-filled with pharmaceutical preparations for treating oncology, hematology, cardiovascular, metabolic and inflammatory diseases and conditions Injectors for medical purposes, namely, medical fluid injectors
Provided herein are processes for preparing Compound A or a salt thereof, comprising admixing Compound B or a salt thereof and crotonaldehyde in the presence of an acid catalyst and a solvent to form Compound A
Provided herein are processes for preparing Compound A or a salt thereof, comprising admixing Compound B or a salt thereof and crotonaldehyde in the presence of an acid catalyst and a solvent to form Compound A
C07D 207/06 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
C07D 213/73 - Unsubstituted amino or imino radicals
The present invention relates to an optimized method of transfecting cells that requires less steps and less DNA than previously disclosed methods. In addition, the method allows for less days in the laboratory for scientists.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
An intermediate bulk shipping container includes a box having an interior cavity and at least one tray including a body defining a plurality of recesses. Each of the plurality of recesses is dimensioned to accommodate a drug delivery device. The body of the at least one tray defines more than four recesses.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
B65B 5/06 - Packaging groups of articles, the groups being treated as single articles
27.
MODULAR VECTOR (MODVEC) SYSTEM: A PLATFORM FOR CONSTRUCTION OF NEXT GENERATION EXPRESSION VECTORS
The present invention is directed to a method for optimizing the expression levels of a multi-chain protein wherein the protein comprises at least two different polypeptide chains. The generation of multi-chain proteins presents great challenges due to the pairing/folding of new quaternary structures composed of multiple polypeptide chains, particularly when pairing antibody heavy and light chains in a multispecific format. Of critical import to efficient and proper assembly of multiple polypeptide chain molecules is expression of the different chains at the proper ratio within the cell. The present invention addresses these issues.
Disclosed herein are methods of producing peptides, including liquid phase peptide synthesis methods in which one or more cycles of peptide elongation are performed in one pot. In particular, the present disclosure provides liquid phase peptide synthesis methods employing solvent systems comprising 2-methyltetrahydrofuran for condensation reactions, as well as convergent liquid phase peptide assembly methods in which benzyl alcohol anchor groups are selectively removed from an N-protected C-protected peptide by base-catalyzed ester hydrolysis.
Disclosed herein are methods of producing peptides, including liquid phase peptide synthesis methods in which one or more cycles of peptide elongation are performed in one pot. In particular, the present disclosure provides liquid phase peptide synthesis methods employing solvent systems comprising 2‑methyltetrahydrofuran for condensation reactions, as well as convergent liquid phase peptide assembly methods in which benzyl alcohol anchor groups are selectively removed from an N‑protected C-protected peptide by base-catalyzed ester hydrolysis.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations used for the treatment of cancer and immune diseases and conditions; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of lupus erythematosus, rheumatoid arthritis, multiple sclerosis, neuromyelitis optica and systemic sclerosis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations used for the treatment of cancer and immune diseases and conditions; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of lupus erythematosus, rheumatoid arthritis, multiple sclerosis, neuromyelitis optica and systemic sclerosis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations used for the treatment of cancer and immune diseases and conditions; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of lupus erythematosus, rheumatoid arthritis, multiple sclerosis, neuromyelitis optica and systemic sclerosis
A method for characterizing and/or aligning product fill recipes includes generating first flow rate data over a plurality of first fill instances corresponding to a first and/or second product fill recipe, generating a plurality of first and/or second fill instance curves, generating a first and/or second flow profile based on the plurality of first and/or second fill instance curves, and causing a display to present the first and/or second flow profile. Another method includes determining, based on the first and second flow profile, adjustments to parameters of the second product fill recipe and changing the parameters of the second product fill recipe in accordance with the adjustments. A system includes one or more flow sensors, one or more processors, and one or more non-transitory, computer-readable media storing instructions that, when executed by the one or more processors, cause the one or more processors to perform any of the methods.
G05D 7/06 - Control of flow characterised by the use of electric means
A61J 1/22 - Arrangements for transferring fluids, e.g. from vial to syringe with means for metering the amount of fluid
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
40.
QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula (I): (Formula (I)) wherein the variables of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula (I): (Formula (I)) wherein the variables of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Pharmaceutical compositions comprising anti-C5 antibody are described herein. Methods comprising administering pharmaceutical compositions are described herein. Methods of manufacturing pharmaceutical compositions are described herein.
Systems and methods of foil packaging components of a drug delivery device comprise introducing a first sheet of foil and a second sheet of foil into a welding assembly, welding the first sheet of foil and the second sheet of foil together at a first subsection of the first and second sheets of foil to define a first welded subsection, providing a component for a drug delivery device between the first sheet of foil and the second sheet of foil above the first welded subsection, unclamping the first welding bar and the second welding bar from the first welded subsection, moving the first sheet of foil and the second sheet of foil downward in the welding assembly, and welding the first sheet of foil and the second sheet of foil together at a second subsection of the first and second sheets of foil to define a second welded subsection.
The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention refers to a crystalline 2-fluoro-3-nitrotoluene compound of formula (I):
The present invention refers to a crystalline 2-fluoro-3-nitrotoluene compound of formula (I):
The present invention refers to a crystalline 2-fluoro-3-nitrotoluene compound of formula (I):
and a process for the preparation thereof. Furthermore, the present invention relates to a process for the synthesis of a compound of formula (II):
The present invention refers to a crystalline 2-fluoro-3-nitrotoluene compound of formula (I):
and a process for the preparation thereof. Furthermore, the present invention relates to a process for the synthesis of a compound of formula (II):
The present invention refers to a crystalline 2-fluoro-3-nitrotoluene compound of formula (I):
and a process for the preparation thereof. Furthermore, the present invention relates to a process for the synthesis of a compound of formula (II):
or salts thereof by means of the crystalline 2-fluoro-3-nitrotoluene.
C07C 205/12 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by halogen atoms having nitro groups bound to carbon atoms of six-membered aromatic rings the six-membered aromatic ring or a condensed ring system containing that ring being substituted by halogen atoms
C07C 201/16 - SeparationPurificationStabilisationUse of additives
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2,2′,2″-(1,3,5,2,4,6-trioxatriborinane-2,4,6-triyl)tris(3-fluorophenol), useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
A robotic inspection platform comprises a robotic arm, an imager, and a controller. The controller causes the robotic arm to retrieve, using its end effector, a container, and to manipulate the container such that the container is sequentially placed in a plurality of orientations while in view of the imager. The controller also causes the imager to capture images, with each of the images being captured while the container is in a respective one of the orientations. The controller also determines one or more attributes of the container, and/or a sample within the container, by analyzing the images using a pattern recognition model and, based on the attribute(s), determines whether the container and/or sample satisfies one or more criteria. If the container and/or sample fails to satisfy the criteria, the controller causes the robotic arm to place the container in an area (e.g., bin) reserved for rejected containers and/or samples.
42 - Scientific, technological and industrial services, research and design
Goods & Services
providing online information about sustainable manufacturing, development initiatives, and strategies to minimize environmental impact within the pharmaceutical manufacturing industry; providing online information involving scientific and technological advancements and the dissemination of knowledge to improve and promote sustainability within the pharmaceutical manufacturing industry
48.
METHODS OF PREPARING HIGH CONCENTRATION LIQUID DRUG SUBSTANCES
Provided herein are methods of preparing a high concentration, liquid composition comprising an oligonucleotide compound. In exemplary embodiments, the method comprises exchanging by diafiltration an oligonucleotide compound in a starting solution into a diafiltration (DF) solution to obtain an intermediate solution, wherein the concentration of the oligonucleotide compound in the starting solution is 140 mg/mL or less and the DF solution comprises one or more salts, and concentrating by ultrafiltration the oligonucleotide compound in the intermediate solution to obtain a high concentration, liquid composition, wherein the concentration of the oligonucleotide compound in the high concentration, liquid composition is greater than about 150 mg/mL.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
49.
AUTOMATED SYSTEMS AND METHODS FOR FOIL PACKAGING COMPONENTS
Systems and methods of foil packaging components of a drug delivery device comprise introducing a first sheet of foil and a second sheet of foil into a welding assembly, welding the first sheet of foil and the second sheet of foil together at a first subsection of the first and second sheets of foil to define a first welded subsection, providing a component for a drug delivery device between the first sheet of foil and the second sheet of foil above the first welded subsection, unclamping the first welding bar and the second welding bar from the first welded subsection, moving the first sheet of foil and the second sheet of foil downward in the welding assembly, and welding the first sheet of foil and the second sheet of foil together at a second subsection of the first and second sheets of foil to define a second welded subsection.
B65B 11/50 - Enclosing articles, or quantities of material, by disposing contents between two sheets, e.g. pocketed sheets, and securing their opposed free margins
B65B 41/10 - Feeding sheets or wrapper blanks by rollers
B65B 51/14 - Applying or generating heat or pressure or combinations thereof by reciprocating or oscillating members
B65B 57/16 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of articles or materials to be packaged and operating to stop, or to control the speed of, the machine as a whole
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 9/00 - Medicinal preparations characterised by special physical form
A container and systems for use during an external sterilization process of a plurality of drug delivery devices are provided. The container may include an outer housing and at least one partition at least partially enclosed by the outer housing. The at least one partition may include a plurality of first dividers and a plurality of second dividers. The at least one partition may also be positioned an open configuration, wherein the plurality of first dividers and the plurality of second dividers cooperate with each other to define a plurality of chambers configured to receive at least one of the plurality of drug delivery devices. The at least one partition may also be positioned in a closed configuration wherein the plurality of chambers are substantially completely collapsed.
Drug delivery devices, sealing members for containers housed within such drug delivery devices, and related methods of assembly are disclosed. The drug delivery device may include a housing, a container disposed in the housing and having an interior volume, a drug disposed in the interior volume, and a septum. The container may have an opening formed in an end surface and which communicates with the interior volume. The septum may include a proximal end inserted through the opening into the interior volume of the container. Additionally, the septum may include a distal end having a flange disposed outwardly of the proximal end and contacting the end surface of the container. At least an end portion of the flange may be made of a material that is permeable to a gaseous sterilizing agent.
The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I),
The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I),
The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I),
an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided arc pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides anti-CCR8 antibodies and antigen-binding fragments thereof, and methods of making and using said anti-CCR8 antibodies and antigen-binding fragments thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
55.
Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising Q-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
56.
QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
The present disclosure provides compounds useful for the inhibition of KRAS G12D, G12V, G12A, G12S or G12C. The compounds have a general Formula I: (I) wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 16/06 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies from serum
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
58.
APPARATUS FOR RESOLVING IMAGING PROBLEMS CAUSED BY THE MENISCUS
A well plate cover includes a base defining a base plane, and a plurality of insertion elements. At least a portion of each of the insertion elements is transparent. Each of the insertion elements is coupled to the base, and extends, in a direction orthogonal to the base plane, from the base to a distal end surface of the insertion element. The distal end surface of each of the insertion elements includes an apex that, when the respective insertion element is inserted into a well of a well plate, extends further into the well than any other portion of the distal end surface. The apex is a point, a line, or a plane having a diameter that is less than one half of a maximum diameter of the distal end surface.
A system may include a container holder configured to (i) hold a container that houses a sample and (ii) rotate the container axially. A system may include a sensor having a sensing axis that passes through the container. A system may include a controller operatively coupled to the container holder and the sensor and configured to: control the container holder to axially rotate the container, control the sensor to capture sensor data of the container at a plurality of axial rotation angles, analyze the captured sensor data to determine a shape of a top surface of the sample; and based on the shape of the top surface, determine a sample volume.
G01B 11/25 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures by projecting a pattern, e.g. moiré fringes, on the object
G01F 22/00 - Methods or apparatus for measuring volume of fluids or fluent solid material, not otherwise provided for
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
61.
SYSTEMS AND METHODS FOR IMPROVED MOLECULE ASSESSMENT
Methods for configuring molecule assessment equipment configured to conduct an automated test that assesses one or more characteristics of a sample under test and systems for implementing the same are provided. The molecule assessment equipment includes a controller that controls an assessment environment in accordance with one or more control parameters. The methods include obtaining sensor data indicative of environmental conditions of a production environment at which the sample under test is to be produced; converting the sensor data to control values of the one or more control parameters; and performing at least one of configuring the controller of the molecule assessment equipment using the control values and presenting the control values via an output device. The molecule assessment equipment is operated to execute the automated test of the sample under test after the controller is configured with the control values.
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Research and development of pharmaceutical preparations; research and development of pharmaceutical preparations in the field of weight reduction, long term weight loss management, and diabetes; medical and scientific research information in clinical trials in the field of weight reduction, long term weight loss management, and diabetes; providing websites featuring medical and scientific research information about the diagnostic, prophylactic and therapeutic properties of pharmaceuticals in the field of weight reduction, long term weight loss management, and diabetes; providing websites featuring medical and scientific research information about pharmaceuticals preparations in the field of weight reduction, long term weight loss management, and diabetes; providing websites that features non-downloadable computer software that enables users to access, manage, update and display electronic databases in the field of weight reduction, long term weight loss management, and diabetes
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Research and development of pharmaceutical preparations; research and development of pharmaceutical preparations in the field of weight reduction, long term weight loss management, and diabetes; medical and scientific research information in clinical trials in the field of weight reduction, long term weight loss management, and diabetes; providing websites featuring medical and scientific research information about the diagnostic, prophylactic and therapeutic properties of pharmaceuticals in the field of weight reduction, long term weight loss management, and diabetes; providing websites featuring medical and scientific research information about pharmaceuticals preparations in the field of weight reduction, long term weight loss management, and diabetes; providing websites that features non-downloadable computer software that enables users to access, manage, update and display electronic databases in the field of weight reduction, long term weight loss management, and diabetes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; pharmaceutical preparations for
the treatment of inflammation and inflammatory diseases and
disorders; pharmaceutical preparations for the treatment of
the respiratory system; pharmaceutical preparations for the
treatment of the gastrointestinal disorders; pharmaceutical
preparations for the treatment of dermatological diseases
and disorders, skin conditions, alopecia, atopic dermatitis,
autoimmune diseases and disorders; pharmaceutical
preparations for the treatment of asthma and other breathing
disorders.
Invention disclosed herein provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent alone, or in combination with an anti-PD-L 1 antibody and/or chemotherapeutic agents. Step dosing or extended IV infusion of the anti-DLL3 agent is also disclosed.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to an antibody construct comprising a first domain which binds to BCMA and a second domain which binds to CD3, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the antibody construct is administered at a specified dose in at least one cycle, wherein one cycle comprises a specified period of administration of the antibody construct. Moreover, the invention relates to a method for the treatment of a BCMA positive neoplasm comprising administering a specified amount of such antibody construct, and the use of such antibody construct for the manufacture of a medicament for the treatment of a BCMA positive neoplasm.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
68.
RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
70.
METHODS OF ANALYZING AMINO ACID CONTENT OF A THERAPEUTIC PROTEIN
Provided herein are methods for analyzing the amino acid content of a therapeutic protein. In exemplary embodiments, the method comprises exchanging by diafiltration the therapeutic protein into a second solution from a first solution to obtain an exchanged protein solution; incubating the exchanged protein solution at an acidic pH at a temperature greater than 110 °C to obtain a hydrolyzed sample comprising amino acids of the therapeutic protein; combining the hydrolyzed sample with activated charcoal; and separating the hydrolyzed sample from the activated charcoal by filtration, centrifugation, or both filtration and centrifugation; and analyzing the amino acid content of the hydrolyzed sample.
The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A drug delivery device includes a housing, an injection assembly at least partially disposed in the housing, a shield, and a drive assembly at least partially disposed in the housing and coupled with the injection assembly and the shield. The shield has an extended position where at least a proximal end thereof extends a distance beyond a proximal end of the housing. The injection assembly includes a needle or cannula having an endpoint. Upon moving the shield axially towards the distal end of the housing a predetermined distance, a retraction profile commences whereby the drive assembly administers a medicament via the injection assembly. A peak resistance force is exerted within approximately the first 12 mm of axial movement of the shield.
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/20 - Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
73.
METHOD OF PREVENTING LAMELLAR SILICA FORMATION IN GLASS CONTAINER
Methods of preventing the formation of lamellar silica formation in a borosilicate glass container storing a pharmaceutical formulation in an interior of the glass container in accordance with embodiments of the disclosure can include washing the container and drying the container under extended dry conditions of at least 3000 ms.
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
B08B 17/02 - Preventing deposition of fouling or of dust
C03C 23/00 - Other surface treatment of glass not in the form of fibres or filaments
G01N 21/90 - Investigating the presence of flaws, defects or contamination in a container or its contents
G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]
KRAS G12CKRAS G12C mutation in a patient in need of treatment, the method comprising administering to the patient (a) a therapeutically effective amount of sotorasib or a pharmaceutically acceptable salt thereof, (b) a therapeutically effective amount of an epidermal growth factor receptor (EGFR) antibody, and (c) (1) a therapeutically effective amount of oxaliplatin, (2) a therapeutically effective amount of leucovorin or a therapeutically effective amount of levoleucovorin, and (3) a therapeutically effective amount of 5-fluorouraciI (5-FU).
Method for investigating subcutaneous administration of a therapeutic compound product comprising providing a live in vitro mammalian skin sample comprising a dermal layer and epidermal layer, administering a therapeutic compound product to the interface between the dermal layer and the epidermal layer and analysing the skin sample.
Antigen-binding proteins that target cancer-associated fibroblasts are provided herein. Methods of treatment comprising administering a pharmaceutical composition comprising an antigen-binding protein as described herein are further provided.
Bispecific molecules that target cancer-associated fibroblasts are provided herein. Methods of treatment comprising administering a pharmaceutical composition comprising a bispecific molecule as described herein are further provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
78.
METHODS FOR ADMINISTERING A BCMAXCD3 BINDING MOLECULE
The present invention relates to the dosage and administration of anti-BCMA x anti-CD3 binding molecules for the treatment of BCMA positive neoplasms. More specifically, the present invention relates to a protein comprising a first domain which binds to BCMA, a second domain which binds to CD3 and a third domain which enhances the half-life of the protein, for use in the treatment or amelioration of a BCMA positive neoplasm, wherein the protein is administered at a specified dose regimen in at least one cycle. Moreover, the invention relates to a method for the treatment or amelioration of a BCMA positive neoplasm comprising administering a specified dose regimen of such binding molecule, to methods for administering therapeutic doses of such binding molecules and to the use of such binding molecules for the manufacture of a medicament for the treatment or amelioration of a BCMA positive neoplasm.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Automatic prefilled syringe inspection systems, apparatus and methods are provided. The automatic syringe inspection systems, apparatus and methods may determine a plunger depth within a syringe that has been pre-filled with a medication. The plunger depth may be based on digital image data that is representative of a silhouette of at least a portion of a tubular vessel and at least a portion of a plunger within the tubular vessel.
G01F 11/02 - Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it with measuring chambers which expand or contract during measurement
The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Methods of isolating a therapeutic protein from a sample are described herein. Kits for isolating a therapeutic protein from a sample are described herein.
Multicomponent polypeptides such as bispecific antibodies comprise multiple unique polypeptide chains, and ensuring their proper quaternary assembly is critical for both efficacy and safety. The present invention relates to purification-based Building Block Compatibility Screening (pBBCS), a new method to select components for the successful integration into multicomponent polypeptides. pBBCS utilizes analysis of physical properties such as the surface charge of those components, and facilitates quickly focusing optimization efforts on only promising candidate components. Therefore, pBBCS can play a critical role in the next-generation workflows for multicomponent polypeptides to enable lower costs, higher speed, and an increase in overall success rates.
This invention provides improved methods for differentiating human pluripotent stem cells into an aorta-gonad-mesonephros-like definitive hemogenic mesoderm capable of giving rise to definitive hematopoietic progenitor and stem cells.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases and disorders; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of the gastrointestinal diseases and disorders; pharmaceutical preparations for the treatment of dermatological diseases and disorders, skin conditions, alopecia, atopic, and dermatitis; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of asthma and other breathing disorders; pharmaceutical preparations for the treatment of obesity, diabetes, cardiovascular, central nervous system diseases and disorders, metabolic disorders, and stroke
Provided herein are methods of treating cancer comprising a KRAS G12C mutation in a patient comprising administering to the patient sotorasib and an anti-epidermal growth factor receptor (EGFR) antibody in amounts effective to treat the cancer. Further provided herein are methods further comprising administering FOLFIRI (irinotecan, 5-FU and leucovorin) to the patient.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for use in the
treatment of hematological, immune, autoimmune, inflammatory
and respiratory diseases and disorders; pharmaceutical
preparations and substances for the treatment of cancer and
cardiovascular diseases and disorders; pharmaceutical
preparations and substances used for the treatment of blood
cells and blood vessel diseases and disorders;
pharmaceutical preparations and substances for the treatment
of oncological, and ophthalmic diseases and disorders;
pharmaceutical preparations and substances for the treatment
of inflammatory disorders of the central nervous system;
pharmaceutical preparations and substances used for the
treatment of hemolytic anemia, thrombocytopenia and kidney
failure.
The present invention relates to improved preparation of a KIF18A inhibitor having the chemical structure Compound (1), or a salt thereof Compound (la); wherein HA is as defined herein; and key intermediates thereof, i.e., Compound (2a), Compound (3a), Compound (5) or a salt thereof, and Compound (6a) or a hydrate thereof, of the formulae: Compound (2a); Compound (3a); Compound (5) or a salt thereof; and Compound (6a) or a hydrate thereof, preferably Compound (6a-1). The present invention further relates to solid form of Compound (6a), preferably the crystalline hydrate form of Compound (6a-1).
The present invention relates to improved preparation of a KIF18A inhibitor having the chemical structure Compound (1), or a salt thereof Compound (la); wherein HA is as defined herein; and key intermediates thereof, i.e., Compound (2a), Compound (3a), Compound (5) or a salt thereof, and Compound (6a) or a hydrate thereof, of the formulae: Compound (2a); Compound (3a); Compound (5) or a salt thereof; and Compound (6a) or a hydrate thereof, preferably Compound (6a-1). The present invention further relates to solid form of Compound (6a), preferably the crystalline hydrate form of Compound (6a-1).
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
An automated visual inspection (AVI) system may include at least one profile view imager having an optical axis that passes through an inspection object, a proximal polarizing film axially aligned with the optical axis, a liquid crystal device axially aligned with the optical axis, a distal polarizing film axially aligned with the optical axis, and at least one light source oriented to emit illumination toward the distal polarizing film. Alternatively, or additionally, an AVI system may include a profile view imager having an optical axis that enters a container through a side wall of the container, and a ring light that is coaxially aligned with a central axis of the container, below the container, and oriented to emit light toward a bottom of the container. The AVI system may also include a bottom imager coaxially aligned with the central axis and oriented to view the bottom of the container.
Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
Provided herein is a process for preparing compound A comprising (a) admixing 2-isopropyl-4-methylpyridin-3-amine (Compound B), or a salt thereof, a first base, and a reactive compound comprising phosgene or a phosgene equivalent in an organic solvent to form 3-isocyanato-2-isopropyl-4-methylpyridine (Compound C); (b) admixing Compound C and 2,6-dichloro-5-fluoronicotinamide (Compound D) to form 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Compound E); and (c) admixing Compound E and a second base to form a product mixture comprising Compound A and the second base. Also provided herein is a process for synthesizing AMG 510 comprising using Compound A prepared according to the disclosed processes
Provided herein is a process for preparing compound A comprising (a) admixing 2-isopropyl-4-methylpyridin-3-amine (Compound B), or a salt thereof, a first base, and a reactive compound comprising phosgene or a phosgene equivalent in an organic solvent to form 3-isocyanato-2-isopropyl-4-methylpyridine (Compound C); (b) admixing Compound C and 2,6-dichloro-5-fluoronicotinamide (Compound D) to form 2,6-dichloro-5-fluoro-N-((2-isopropyl-4-methylpyridin-3-yl)carbamoyl)nicotinamide (Compound E); and (c) admixing Compound E and a second base to form a product mixture comprising Compound A and the second base. Also provided herein is a process for synthesizing AMG 510 comprising using Compound A prepared according to the disclosed processes
The present invention provides single chain T cell engager (TCE) molecules having an scFab that binds a target antigen and an scFv that binds CD3, and TCE molecules that bind CCR8 and CD3. Methods of treating cancer are also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
97.
EVALUATION OF MRNA TRANSCRIPT LEVELS USING DDPCR FOR EARLY POOL AND SINGLE-CELL CLONE ASSESSMENT IN CELL LINE DEVELOPMENT
The present disclosure relates the field of cell culture technology. It provides a method of facilitating selection of a single cell clone or pools of cells for manufacturing an antigen-binding protein with two to four different antibody chains. The method utilizes ddPCR for the quantification of transcript levels.
The present disclosure provides compounds useful for the inhibition of KRAS. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
The present disclosure provides compounds useful for the inhibition of KRAS. The compounds have a general Formula I: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, cancer.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GLP-1 RECEPTOR AGONISTS CONJUGATED TO ANTAGONISTS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)
Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
